Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Eli Lilly

Merck

Moderna

Novo Nordisk

Pfizer

Sanofi

With economic worries unsettling investors, it is not surprising that leading advisors, and contributors to MoneyShow.com, are looking to the pharmaceutical sector – Here's a look at seven global favorites, focused on such areas as obesity and diabetes to new applications for mRNA-based vaccines.

7 Healthy Buys Among Global Drug Makers

BERKELEY, Calif.--( BUSINESS WIRE )--Bayer will invest more than $1.5 million in Berkeley working with 13 non-profits to drive resiliency in its West Berkeley neighborhood and to advance Science, Technology, Engineering, Arts and Math (STEAM) education over the next three to five years. Sponsorship of these programs is part of Bayer's recently Amended and Restated Development Agreement (ARDA) with the City of Berkeley which outlines more than $33 million in community investments to be made over the next 30 years as the company transforms its biotech operations there.

Bayer to make more than $1.5 Million in Investments in STEAM Education and West Berkeley Resiliency

The Roundup acquisition has cost Bayer AG billions in lawsuits; however, this seems to be coming to an end as the company has been winning most cases recently. Bayer boasts a strong and improving balance sheet with a P/B ratio of just 1.26 and IP with a strong moat. Furthermore, earnings and free cash flow are rising.

Bayer AG: Turnaround Value Stock

Bayer has reached a $698 million deal with the state of Oregon ending a lawsuit over PCB pollution, larger than any other state settlement over PCB contamination.

Monsanto ends Oregon PCB pollution lawsuit with $698M deal

A French court has ordered Germany's Bayer to pay compensation of some 11,000 euros ($11,560) to a crop farmer for the accidental inhalation of a weedkiller, ending a 15-year legal battle, his lawyer and the company said on Thursday.

French farmer awarded 11,000 euros over Bayer pesticide inhalation

LEVERKUSEN, Germany & WASHINGTON--( BUSINESS WIRE )--Today, Bayer announced the U.S. launch of the Bayer Science Collaboration Explorer (BSCE) as part of its ongoing efforts to enhance public trust in scientific innovations, processes, and R&D activities. The Explorer is a publicly accessible database where Bayer shares information on its science collaborations and new contracts with universities, public research institutions, and individuals.

Bayer Launches Industry-First Public Database Listing Company's Science Collaborations and Partnerships in the U.S.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Bayer Aktiengesellschaft (BAYRY) is a Top Value Stock for the Long-Term

PITTSBURGH--( BUSINESS WIRE )--As international leaders in the field of Imaging gather for the 2022 Radiological Society of North America (RSNA) Annual Meeting, Bayer Radiology, a leader in diagnostic imaging, will showcase its portfolio of products and solutions intended to address today's most pressing issues facing the field of Radiology. In addition, Bayer will present new scientific data on an investigational contrast agent. The 2022 RSNA will take place from November 27 to December 1 in Chicago.

2022 Radiological Society of North America (RSNA) Annual Meeting: Bayer to showcase product offerings and announces broadened AI offering in Radiology

BASF SE

Ford Motor Company

Barrick Gold

Orange

Stellantis N.V. 

Vale S.A.

Cheap blue-chip stocks under $15 can be rare finds. Typically since financially sound firms with recognizable names have histories of strong performance and often include dividends, their prices tend to be higher.

7 Cheap Blue-Chip Stocks Under $15 to Buy Now

DAVIS, Calif.--( BUSINESS WIRE )--OpenFold, a non-profit artificial intelligence (AI) research consortium whose goal is to develop free and open source software tools for biology and drug discovery, today announced the addition of four new industry members: Bayer, Dassault Systèmes, CHARM Therapeutics, and BaseCamp Research Ltd.

OpenFold AI Research Consortium Welcomes 4 New Members: Bayer, Dassault, CHARM Therapeutics and BaseCamp Research

BAYRY vs. NVO: Which Stock Is the Better Value Option?

Bayer (BAYRY) gets positive recommendation from the CHMP for label extension of ophthalmology drug Eylea for the treatment of preterm infants with retinopathy of prematurity.

Bayer (BAYRY) Eylea Label Extension Gets CHMP Positive Opinion

Bayer AG (OTCPK:BAYZF) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Oliver Maier - Head, IR Werner Baumann - Chairman, CEO & Chief Sustainability Officer Wolfgang Nickl - CFO Heiko Schipper - President, Consumer Health Division Rodrigo Santos - President, Crop Science Division Stefan Oelrich - Head, Pharmaceuticals Division Conference Call Participants Michael Leuchten - UBS Richard Vosser - JPMorgan Chase & Co. Peter Verdult - Citi Vincent Andrews - Morgan Stanley Sachin Jain - Bank of America Merrill Lynch Laurent Favre - Exane BNP Paribas Dominic Lunn - Crédit Suisse Keyur Parekh - Goldman Sachs James Quigley - Morgan Stanley Falko Friedrichs - Deutsche Bank Operator Good day, and thank you for standing by. Welcome to Bayer's Investor and Analyst Conference Call on the Third Quarter 2022 Results.

Bayer AG (BAYZF) Q3 2022 Earnings Call Transcript

Bayer's (BAYRY) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.

Bayer's (BAYRY) Q3 Earnings Miss Estimates, Revenues Top

Bayer, together with the Bill & Melinda Gates Foundation, are jointly funding pre-clinical research in non-hormonal contraception

Bayer Signs Grant Agreement to Advance Research in Non-Hormonal Contraception

Bayer AG on Tuesday backed its 2022 financial objectives after third-quarter sales beat expectations and it reported earnings growth in all its segments.

Bayer backs outlook after forecast beating sales of €11.28 billion

Agriculture and pharmaceuticals company Bayer on Tuesday reported better-than-expected quarterly earnings as surging demand for its herbicides made up for a decline in sales of its stroke prevention pill Xarelto.

Bayer beats Q3 profit forecast on strong herbicide sales

OASIS- 4 plans to investigate elinzanetant as a non-hormonal treatment for vasomotor symptoms caused by endocrine therapy in breast cancer patients

Outside the US Bayer Extends Development Program for Investigational Product Elinzanetant With Phase III Study in Breast Cancer Patients With Vasomotor Symptoms Caused by Endocrine Therapy

Bestinfond (Trades, Portfolio), a fund that is part of Spain-based Bestinver, disclosed in a recent regulatory filing that its top trades during the third quarter included new holdings in Bayer AG ( XTER:BAYN , Financial) and Banco Bilbao Vizcaya Argentaria SA ( XMAD:BBVA , Financial), the closure of its positions in easyJet PLC ( LSE:EZJ , Financial) and Repsol SA (XMAD:REP) and a reduction to its holding in Intesa Sanpaolo ( MIL:ISP , Financial).

Bestinfond Opens Stake in Bayer, Discards easyJet in 3rd Quarter

Further post-hoc analysis from FIDELITY, a prespecified, exploratory pooled analysis of FIDELIO-DKD and FIGARO-DKD Phase III studies, investigates the efficacy and safety of KERENDIA in patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) who have sustained an acute change in estimated glomerular filtration rate (eGFR) upon drug initiation1

Bayer to Highlight Additional Analyses From Comprehensive KERENDIA® (finerenone) Clinical Trial Program at the American Society of Nephrology's 2022 Kidney Week

Bayer Aktiengesellschaft (BAYRY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bayer Aktiengesellschaft (BAYRY) Upgraded to Buy: Here's Why

BAYRY or NVO: Which Is the Better Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Bayer (BAYRY) a Great Value Stock Right Now?

AP Moller - Maersk A/S

GlaxoSmithKline

Himax Tech

Ituran Location & Control

Bank of N.T. Butterfield & Son

Schneider Electric SE

Sibanye Stillwater

Telefonica Brasil

Vodafone Group

Subscribers to my Dividend Dogcatcher Marketplace (behind the SA paywall) know my Viital portfolio (#VII) stocks are “selected based-on gains, yield, momentum, price-upside, dividend-history, analyst-interest, special-market qualities, and dividend-safety.”. By yield, HIMX topped-all Viital eX-US candidates. Top-ten Yields from NTB, EMBVF, BCE, SBSW, GSK, VOD, VALE, CRARF, AMKBY, and HIMX averaged 9.94%.

15 Top October Ex-U.S. Dividend Dogs, Which One To Buy?

Bayer's KERENDIA® (finerenone), a first-in-class, non-steroidal mineralocorticoid receptor antagonist (ns-MRA), was recommended as part of a comprehensive treatment strategy for patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) in a newly published update to the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease and in a consensus report jointly issued by KDIGO and the American Diabetes Association (ADA).1-3

Bayer's KERENDIA® (finerenone) Recommended as Part of Comprehensive Treatment Strategy for Chronic Kidney Disease Associated With Type 2 Diabetes in Newly Published Clinical Recommendations

News for Bayer AG Stock (BAYRY)